Intrinsically unstructured domain 3 of hepatitis C virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Gupta, Garvita ^a   Qin, Haina ^a   Song, Jianxing ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A4; NONSTRUCTURAL PROTEIN 5A; SYNAPTOBREVIN; UNCLASSIFIED DRUG; VAP B PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CIRCULAR DICHROISM; COMPLEX FORMATION; DISSOCIATION CONSTANT; HEPATITIS C VIRUS; HETERONUCLEAR SINGLE QUANTUM COHERENCE; INTRINSICALLY UNSTRUCTURED THIRD DOMAIN; MOLECULAR CLONING; MOLECULAR DOCKING; MSP DOMAIN; MUTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; CIRCULAR DICHROISM; HUMANS; MODELS, THEORETICAL; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84862227635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039261     Document Type: Article

References (84)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-562.
2. Fusco DN, Chung RT, (2012) Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. Annu Rev Med 63: 373-387.
3. Wasley A, Alter MJ, (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1-16.
4. Zoulim F, Chevallier M, Maynard M, Trepo C, (2003) Clinical consequences of hepatitis C virus infection. Rev Med Virol 13: 57-68.
5. Dubuisson J, Helle F, Cocquerel L, (2008) Early steps of the hepatitis C virus life cycle. Cell Microbiol 10: 821-827.
6. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, et al. (1993) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 90: 10773-10777.
7. Moriishi K, Matsuura Y, (2003) Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 14: 285-297.
8. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM, (1993) Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67: 1385-1395.
9. Lohmann V, Koch JO, Bartenschlager R, (1996) Processing pathways of the hepatitis C virus proteins. J Hepatol 24: 11-19.
10. Shi S, Lee TKJ, Aizaki H, Hwang SB, Lai MM, (2003) Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol 77: 4160-4168.
11. Aizaki H, Lee K, Sung VMH, Ishiki H, Lai MM, (2004) Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324: 450-461.
12. Ali N, Tardif KD, Siddiqui A, (2002) Cell-free replication of the hepatitis C virus subgenomic replicon. J Virol 76: 12001-12007.
13. Hardy RW, Marcotrigiano J, Blight KJ, Majors JE, Rice CM, (2003) Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol 77: 2029-2037.
14. Yang G, Pevear DC, Collett MS, Chunduru S, Young DC, et al. (2004) Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s). J Virol 78: 10202-10205.
15. Gao L, Aizaki H, He JW, Lai MM, (2004) Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 78: 3480-3488.
16. Evans MJ, Rice CM, Goff SP, (2004) Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 101: 13038-12043.
17. Hamamoto I, Nishimura Y, Okamoto T, Aizaki H, Liu M, et al. (2005) Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol 79: 13473-13482.
18. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
19. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
20. Rice CM, (2011) New insights into HCV replication: potential antiviral targets. Top Antivir Med 19: 117-20.
21. Bühler S, Bartenschlager R, (2012) New targets for antiviral therapy of chronic hepatitis C. Liver Int 32: 9-16.
22. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM, (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56.
23. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S, (2011) An overview of HCV molecular biology, replication and immune responses. Virol J 8: 161.
24. Kwo PY, Vinayek R, (2011) The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 5: 406-417.
25. Halfon P, Locarnini S, (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206.
26. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K, (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38: 1282-1288.
27. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, et al. (2009) Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5: e1000546.
28. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, et al. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100.
29. Lemm JA, O'Boyle D 2nd, Liu M, Nower PT, Colonno R, et al. (2010) Identification of hepatitis C virus NS5A inhibitors. J Virol 84: 482-491.
30. Asselah T, (2011) NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 54: 1069-1072.
31. Ranjith-Kumar CT, Wen Y, Baxter N, Bhardwaj K, Cheng Kao C, (2011) A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A. PLoS One 6: e22575.
32. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM, (2008) Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 82: 1073-1083.
33. Yamasaki LH, Arcuri HA, Jardim AC, Bittar C, de Carvalho-Mello IM, et al. (2012) New insights regarding HCV-NS5A structure/function and indication of genotypic differences. Virol J 9: 14.
34. Tellinghuisen TL, Marcotrigiano J, Rice CM, (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435: 374-379.
35. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN, (2009) Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83: 4395-4403.
36. Liang Y, Ye H, Kang CB, Yoon HS, (2007) Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry 46: 11550-11558.
37. Hanoulle X, Badillo A, Verdegem D, Penin F, Lippens G, (2010) The domain 2 of the HCV NS5A protein is intrinsically unstructured. Protein Pept Lett 17: 1012-1018.
38. Hanoulle X, Verdegem D, Badillo A, Wieruszeski JM, Penin F, et al. (2009) Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun 381: 634-638.
39. Verdegem D, Badillo A, Wieruszeski JM, Landrieu I, Leroy A, et al. (2011) Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem 286: 20441-20454.
40. Skehel PA, Martin KC, Kandel ER, Bartsch D, (1995) AVAMP-binding protein from Aplysia required for neurotransmitter release. Science 269: 1580-1583.
41. Nishimura Y, Hayashi M, Inada H, Tanaka T, (1999) Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem. Biophys Res Commun 254: 21-26.
42. Nachreiner T, Esser M, Tenten V, Troost D, Weis J, et al. (2010) Novel splice variants of the amyotrophic lateral sclerosis-associated gene VAPB expressed in human tissues. Biochem Biophys Res Commun 394: 703-708.
43. Skehel PA, Fabian-Fine R, Kandel ER, (2000) Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc Natl Acad Sci USA 97: 1101-1106.
44. Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, et al. (2005) Structural basis of FFAT motif-mediated ER targeting. Structure 13: 1035-1045.
45. Furuita K, Jee J, Fukada H, Mishima M, Kojima C, (2010) Electrostatic interaction between oxysterol-binding protein and VAMP-associated protein A revealed by NMR and mutagenesis studies. J Biol Chem 285: 12961-12970.
46. Shi J, Lua S, Tong JS, Song J, (2010) Elimination of the native structure and solubility of the hVAPB MSP domain by the Pro56Ser mutation that causes amyotrophic lateral sclerosis. Biochemistry 49: 3887-3897.
47. Olkkonen VM, (2004) Oxysterol binding protein and its homologues: New regulatory factors involved in lipid metabolism. Curr Opin Lipidol 15: 321-327.
48. Holthuis JC, Levine TP, (2005) Lipid traffic: Floppy drives and a superhighway. Nat Rev Mol Cell Biol 6: 209-220.
49. Wyles JP, McMaster CR, Ridgway ND, (2002) Vesicle associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum. J Biol Chem 277: 29908-29918.
50. Tsuda H, Han SM, Yang Y, Tong C, Lin YQ, et al. (2008) The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 133: 963-977.
51. Lua S, Qin H, Lim L, Shi J, Gupta G, et al. (2011) Structural, stability, dynamic and binding properties of the ALS-causing T46I mutant of the hVAPB MSP domain as revealed by NMR and MD simulations. PLoS One 6: e27072.
52. Nishimura AL, Al-Chalabi A, Zatz M, (2005) A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population. Hum Genet 118: 499-500.
53. Chen HJ, Anagnostou G, Chai A, Withers J, Morris A, et al. (2010) Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 285: 40266-40281.
54. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM, (2004) Structural biology of hepatitis C virus. Hepatology 39: 5-19.
55. Lim SP, Khu YL, Hong WJ, Tay A, Ting AE, et al. (2001) Identification and molecular characterisation of the complete genome of a Singapore isolate of hepatitis C virus: sequence comparison with other strains and phylogenetic analysis. Virus Genes 23: 89-95.
56. Dosztányi Z, Csizmók V, Tompa P, Simon I, (2005) IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21: 3433-3434.
57. Song J, (2009) Insight into "insoluble proteins" with pure water. FEBS Lett 583: 953-9.
58. Dyson HJ, Wright PE, (2001) Nuclear magnetic resonance methods for elucidation of structure and dynamics in disordered states. Methods Enzymol 339: 258-270.
59. Bai Y, Chung J, Dyson HJ, Wright PE, (2001) Structural and dynamic characterization of an unfolded state of poplar apoplastocyanin formed under nondenaturing conditions. Protein Sci 10: 1056-1066.
60. Dyson HJ, Wright PE, (2005) Intrinsically unstructured proteins and their functions, Nat Rev Mol Cell Biol 6: 197-208.
61. Tompa P, (2002) Intrinsically unstructured proteins. Trends Biochem Sci 27: 527-533.
62. Gunasekaran K, Tsai CJ, Kumar S, Zanuy D, Nussinov R, (2003) Extended disordered proteins: targeting function with less scaffold. Trends Biochem Sci 28: 81-85.
63. Wright PE, Dyson HJ, (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 293: 321-331.
64. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, et al. (2001) Intrinsically disordered protein. J Mol Graph Model 19: 26-59.
65. Song J, Chen Z, Xu P, Gingras R, Ng A, et al. (2001) Molecular interactions of the Gb binding domain of the Ste20p/PAK family of protein kinases. An isolated but fully functional Gb binding domain from Ste20p is only partially folded as shown by heteronuclear NMR spectroscopy. J Biol Chem 276: 41205-41212.
66. Li M, Song J, (2007) The N- and C-termini of the human Nogo molecules are intrinsically unstructured: bioinformatics, CD, NMR characterization, and functional implications. Proteins 68: 100-108.
67. Liu J, Song J, (2008) A novel nucleolar transcriptional activator ApLLP for long-term memory formation is intrinsically unstructured but functionally active. Biochem Biophys Res Commun 366: 585-91.
68. Tompa P, Fuxreiter M, (2008) Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci 33: 2-8.
69. Fuxreiter M, (2012) Fuzziness: linking regulation to protein dynamics. Mol Biosyst 8: 168-177.
70. Liu J, Li M, Ran X, Fan JS, Song J, (2006) Structural insight into the binding diversity between the human Nck2 SH3 domains and proline-rich proteins. Biochemistry 45: 7171-7184.
71. Miao L, Qin H, Koehl P, Song J, (2011) Selective and specific ion binding on proteins at physiologically-relevant concentrations. FEBS Lett 585: 3126-3132.
72. Qin H, Pu HX, Li M, Ahmed S, Song J, (2008) Identification and structural mechanism for a novel interaction between a ubiquitin ligase WWP1 and Nogo-A, a key inhibitor for central nervous system regeneration. Biochemistry 47: 13647-13658.
73. Qin H, Shi J, Noberini R, Pasquale EB, Song J, (2008) Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J Biol Chem 283: 29473-29484.
74. Tao YJ, Ye Q, (2010) RNA virus replication complexes. PLoS Pathog 6: e1000943.
75. Denison MR, (2008) Seeking membranes: positive-strand RNA virus replication complexes. PLoS Biol 6: e270.
76. Akhvlediani T, Kvirkvelia N, Shakarishvili R, Tsertsvadze T, (2009) Als-like syndrome in the patient with chronic hepatitis C. Georgian Med News (172-173): 70-72.
77. Bastos AF, Orsini M, Machado D, Mello MP, Nader S, et al. (2011) Amyotrophic lateral sclerosis: one or multiple causes? Neurol Int 3: e4.
78. Cheng Y, LeGall T, Oldfield CJ, Mueller JP, Van YY, et al. (2006) Rational drug design via intrinsically disordered protein. Trends Biotechnol 24: 435-442.
79. Metallo SJ, (2010) Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 14: 481-488.
80. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T, (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411-2423.
81. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6: 277-293.
82. Johnson BA, Blevins RA, (1994) NMRView: a computer program for the visualization and analysis of NMR data. J Biomol NMR 4: 603-614.
83. de Vries SJ, van Dijk ADJ, Krzeminski Ml, van Dijk M, Thureau A, et al. (2007) HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69: 726-733.
84. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallographica Section D 54: 905-921.